☆ 4.7 Article

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

EUROPEAN HEART JOURNAL (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Cardiac & Cardiovascular Systems

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

Rajiv Agarwal et al.

Summary: This review covers the development of mineralocorticoid receptor antagonists (MRAs) over the last 80 years, discussing the differences in mechanisms and effects between nonsteroidal and steroidal MRAs. Nonsteroidal MRAs demonstrate important distinctions in distribution, binding mode, and gene expression compared to steroidal MRAs.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Serum potassium and heart failure: association, causation, and clinical implications

Dimitrios Sfairopoulos et al.

Summary: The article discusses the impact of hypo- and hyperkalemia in patients with heart failure, suggesting that low potassium and low-normal potassium levels may be associated with adverse clinical outcomes, while a cause-and-effect relationship between hyperkalemia and adverse clinical outcomes is less likely. The study recommends maintaining serum potassium levels within the range of 4.0-5.0 mmol/L in HF.

HEART FAILURE REVIEWS (2021)

添加到收藏夹

Article Endocrinology & Metabolism

11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2021

Summary: The American Diabetes Association (ADA) Standards of Medical Care in Diabetes provides clinical practice recommendations, treatment goals, and tools for evaluating care quality for diabetes patients. The ADA Professional Practice Committee is responsible for updating these standards, and readers can provide feedback on the standards on the website.

DIABETES CARE (2021)

添加到收藏夹

Article Urology & Nephrology

Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage

Peter Kolkhof et al.

Summary: This study compared the effects of nonsteroidal MR antagonist finerenone and SGLT2 inhibitor empagliflozin as monotherapy and in combination in a preclinical model of hypertension-induced cardiorenal disease. The low-dose combination therapy showed superior outcomes in reducing proteinuria, blood pressure, plasma markers, and cardiorenal lesions compared to respective monotherapy dosages.

AMERICAN JOURNAL OF NEPHROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

Bertram Pitt et al.

Summary: Finerenone therapy improved cardiovascular outcomes in patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, compared to placebo. The risk of the primary outcome event was significantly lower in the finerenone group, primarily driven by a reduction in hospitalization for heart failure.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years

Claire A. Lawson et al.

Summary: In patients with new onset heart failure, those with type 2 diabetes or chronic kidney disease have higher rates of hospitalization and death, with the worst outcomes seen in those with both comorbidities. Over time, cardiovascular hospitalization rates significantly increased for patients with comorbid CKD, while decreasing for those with comorbid T2D.

ECLINICALMEDICINE (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

Rajiv Agarwal et al.

Summary: This review summarizes the development of mineralocorticoid receptor antagonists over the past 80 years, focusing on the mechanisms of action and advantages of nonsteroidal MRAs.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases A Nationwide Study

Bochra Zareini et al.

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2020)

添加到收藏夹

Article Medicine, General & Internal

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J. L. Heerspink et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

George L. Bakris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials

Thomas A. Zelniker et al.

CIRCULATION (2019)

添加到收藏夹

Article Medicine, General & Internal

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

V. Perkovic et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Review Endocrinology & Metabolism

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

Brendan L. Neuen et al.

LANCET DIABETES & ENDOCRINOLOGY (2019)

添加到收藏夹

Article Urology & Nephrology

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial

Luis M. Ruilope et al.

AMERICAN JOURNAL OF NEPHROLOGY (2019)

添加到收藏夹

Article Urology & Nephrology

Diabetic Kidney Disease Challenges, Progress, and Possibilities

Radica Z. Alicic et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Piotr Ponikowski et al.

EUROPEAN HEART JOURNAL (2016)

添加到收藏夹

Article Urology & Nephrology

GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration

Andrew S. Levey et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2014)

添加到收藏夹

Article Medicine, General & Internal

Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality

Josef Coresh et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)

添加到收藏夹

Article Medicine, General & Internal

Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy

Linda F. Fried et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Medicine, General & Internal

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis

Caroline S. Fox et al.

LANCET (2012)

添加到收藏夹

Article Medicine, General & Internal

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

Hans-Henrik Parving et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study

E. Imai et al.

DIABETOLOGIA (2011)

添加到收藏夹

Article Medicine, General & Internal

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

BM Brenner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)

添加到收藏夹

Article Medicine, General & Internal

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

EJ Lewis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.